Nationwide Distribution of Palivizumab Begins to Combat RSV

BUENOS AIRES⁣ (AP) — The Ministry of ⁢Health has ⁣initiated‍ a nationwide distribution of ‍Palivizumab, a monoclonal⁣ antibody crucial in preventing severe lower respiratory infections caused by the respiratory syncytial virus (RSV).

Targeting Vulnerable Infants

The antibody is specifically ‍intended for infants born‍ prematurely,up ‍to 32 weeks of gestational age,or those weighing up to 1,500 grams (3.3 pounds). It is indeed also vital for children with severe congenital heart ‍disease, who are at higher risk of complications from RSV.

Two-Phased Distribution Plan

The distribution is being carried‍ out in⁤ two phases, tailored to the ‍existing⁤ stock levels in each jurisdiction. The initial ‍phase ⁤involves the distribution of more than 1,100 ampoules to the Autonomous City of Buenos Aires and the province of Buenos Aires.As of May 5, an additional 1,700-plus ampoules will be delivered to the remaining jurisdictions.

A second stage,‍ planned for the last week of June, will be adjusted based on patient registries⁢ to minimize waste and ensure efficient ⁢allocation of resources.

National Health Portfolio Commitment

To ensure⁢ nationwide availability within the public health system, the national health portfolio has acquired 4,000 units of Palivizumab and expanded its purchase orders. ⁤The treatment is intended for children discharged from public neonatology services who meet the ‍aforementioned clinical criteria.

Officials say that ⁤as‍ the introduction of Palivizumab into the preventative strategy, there has been a substantial decrease in the number of at-risk children requiring hospitalization due to RSV, ⁤along with a⁤ reduction in severe ‍complications and mortality rates.

RSV Impact on Infant Mortality

Premature births⁣ account for 43% of deaths within the ‍first year of life. RSV is a leading cause‍ of lower ⁢airway infections in children under 2. Infection by⁤ RSV does not provide lasting immunity,⁣ leading to repeat infections, increased ⁣outpatient ⁣visits, hospitalizations, and potential complications⁣ requiring critical ‍care, particularly during winter months.

Increased Risk for Infants with Comorbidities

While RSV ‍affects the broader pediatric population, infants with risk factors, ⁤such as severe congenital heart disease, face a heightened risk of severe respiratory infections. This can led⁢ to a greater need for oxygen therapy, increased admissions ‍to intensive care units,⁤ and ⁤a higher likelihood of requiring mechanical ventilation.

Broader Strategy for Respiratory Disease Prevention

As part of a broader strategy to prevent acute respiratory diseases, the National Health Portfolio incorporated the RSV vaccine for pregnant women between 32 and 36 weeks of gestation, beginning March 1, 2024, during peak viral circulation. Moreover, supplies of Salbutamol, Budesonide, spacers, and ⁤high-flow cannulas, distributed last November, have already been delivered as part of the winter preparedness campaign.

Efforts to Reduce Infant mortality

These initiatives reflect ⁤the Ministry of Health’s ongoing efforts to support provinces in reducing infections among ⁣infants under 6 months. The goal is to contribute to a decrease in both‍ neonatal and post-neonatal infant mortality rates, and also to alleviate the strain on general internment rooms and pediatric and neonatal intensive⁢ care beds caused by the virus.